Foreign Tablets in the Bottle: What Two Metoclopramide Recalls Teach Repackagers and Relabellers

A recall rarely starts where it ends. A tablet made in one plant can be shipped as bulk or finished stock, repackaged or relabelled at a second site, and dispensed from a third. Each handoff is a chance for a mix-up to enter, and a chance to catch one. When two recalls for the same product and the same defect land within eight days of each other, that chain is on full display.

For Canadian licence holders that package, label, import or distribute finished drugs, the question is not whether this could happen to a competitor. It is whether your incoming checks, your line clearance and your recall system would catch a foreign tablet before it reached a patient, and whether your records would survive a Health Canada inspection if they did not. This article walks through the controls that matter, grounded in the Food and Drug Regulations and Health Canada's Good Manufacturing Practices Guide (GUI-0001).

What happened: two recalls, eight days apart

What is it? Two separate recalls of metoclopramide 5 mg oral tablets, a generic version of Reglan used for reflux and gastric motility. Both recalls cited the presence of foreign tablets or capsules, meaning the wrong product was found inside sealed packages. Why it matters? The second recall came from a repackager whose product is attributed on its label to the first company, which shows how a packaging mix-up can surface downstream. What to do? Treat an upstream recall of a product you handle as a trigger to check your own lots, not as someone else's problem.

According to recall reporting that cites the United States Food and Drug Administration (FDA) Enforcement Reports, the figures were as follows. Confirm current status and lot numbers against the FDA Enforcement Report database before acting on any specific lot.

A Class II recall means the product may cause temporary or medically reversible harm, with a low probability of serious harm. In Canada, Health Canada uses a similar three-tier scheme. If you are unsure how a defect would be classified here, our guide to how Canada classifies a product recall breaks down Type I, II and III and what each signals to an inspector.

What a repackager or relabeller actually does under Canadian law

What is it? Packaging and labelling are licensable activities in their own right. A site that places bulk tablets into bottles or blisters, or applies a new label to an authorized drug, is performing a regulated step, not a clerical one. Why it matters? The activity carries the full weight of Good Manufacturing Practices, including quality control release. How it affects compliance? You need a Drug Establishment Licence (DEL) that lists the activity, and your site must meet Division 2 of the Food and Drug Regulations.

Under the Food and Drug Regulations, section C.01A.008, the licensable activities for a drug establishment include fabricate, package or label, test, import, distribute and wholesale. Packaging and labelling is a distinct category. Health Canada's Guidance on Drug Establishment Licences (GUI-0002) sets out how to apply and what each activity covers. If you import a foreign authorized drug and relabel it for the Canadian market, read our explainer on designated drugs on a DEL first, because the obligations are often deeper than firms expect.

The core point: a packager, labeller or repackager holds a quality control department under C.02.013 and must approve each lot before it is sold under C.02.014. That release decision is not a rubber stamp. It must consider production conditions, in-process results and compliance with specifications. A foreign tablet in a bottle is a specification failure that quality control is meant to stop.

How a source defect reaches the repackager's bottle

What is it? A defect such as a mix-up, cross-contamination or commingling that starts at the fabricator and is carried forward in the material a downstream site receives. Why it matters? If the incoming material already contains the wrong tablet, every downstream step inherits the problem unless a control catches it. What to do? Build catch points at receipt and at the line, and hold the upstream supplier to a written quality agreement.

Foreign tablets reach a bottle in a few well understood ways. A shared packaging line was not cleared of the previous product. Bulk containers were commingled during transfer or storage. A feed hopper or chute retained units from an earlier run. Or the source lot already held stray units when it arrived. For a repackager, the last cause is the dangerous one, because it means the defect is invisible unless incoming inspection and line clearance are rigorous.

This is the same failure mode behind other 2026 packaging recalls. Our analysis of the Novo-Gesic Forte recall shows how equipment and material controls fail, and our review of returned goods control after the Aleve Type III recall shows how a product can re-enter the stream carrying a hidden defect. The common thread is that the control closest to the defect is the cheapest place to stop it.

Incoming inspection and identity testing: the first catch point

What is it? The receipt, quarantine, sampling and testing of material before it is released for use. Why it matters? It is the first and often the only chance to detect a defect that is already in the incoming lot. How it affects compliance? Health Canada expects materials to be quarantined, sampled, tested and released before use, and a foreign tablet is exactly what a visual and identity check should catch.

GUI-0001 interprets C.02.009 and C.02.010 to require that each lot of material be sampled and tested against specifications before use, with identity confirmed. For a repackager receiving bulk or finished dosage units, incoming control should include a documented visual examination for foreign or mismatched units, an identity check appropriate to the dosage form, and a reconciliation of received quantity against the supplier's documentation. Quality control must approve the material before it enters packaging, not after.

Where the upstream supplier is a foreign site, the strength of your incoming control is often all that stands between a source defect and a patient. A disciplined supplier qualification programme with risk tiering and audit depth tells you how much to trust a supplier's own release, and therefore how much to inspect on receipt.

Line clearance and reconciliation: the second catch point

What is it? Line clearance is the documented check that a packaging area and its equipment are free of any product, component or label from a previous run before a new run starts. Reconciliation is the count that confirms what went in matches what came out. Why it matters? These two controls catch mix-ups introduced at your own site and expose discrepancies that signal a problem. What to do? Make line clearance a signed, witnessed step and investigate every reconciliation gap before release.

GUI-0001 interprets C.02.011 to require that, before any processing operation, documented steps confirm the work area and equipment are clean and free of prior materials or labels. Operations on different products should not run at the same time, or back to back in the same room, unless there is no risk of mix-up or cross-contamination. Our deep dive on packaging line clearance walks through how a single missed clearance turned into a recall.

Reconciliation is the second half. Health Canada expects packaging orders to record a reconciliation of printed packaging material and bulk drug used, destroyed or returned to stock, and to investigate and account for any significant or unusual discrepancy before release. A count that does not balance is a signal. If 240,448 cartons leave a line and the bulk count does not reconcile, the quality unit should be investigating a mix-up, not releasing stock.

When the source manufacturer recalls: the repackager's obligations

What is it? The actions a downstream site must take when a supplier recalls a product or lot that the site has repackaged, relabelled, imported or distributed. Why it matters? Your obligation to retrieve affected product is independent of the upstream firm's recall. How it affects compliance? You must be able to recall completely and rapidly, trace every lot, and act without waiting to be told.

Under C.02.012, every licence holder must maintain a system of control that permits the complete and rapid recall of any lot or batch on the market. When a supplier recalls, a repackager should immediately identify which of its own lots used the affected source material, quarantine any stock on hand, notify customers down to the level it distributed, and assess health risk. A strong lot traceability system is what makes this possible in hours rather than days.

A quality agreement with the source manufacturer should spell out who notifies whom, how fast, and with what information. Firms that rely on hearing about a recall through the news, or through a customer complaint, have already lost the time that a Class I or Class II situation does not give back. For the accountability picture when an upstream partner fails, see our piece on who is accountable when a contract manufacturer fails. Health Canada's GMP inspection readiness self-assessment is a good way to pressure-test whether your recall and traceability controls would actually hold.

Repackager and relabeller compliance checklist

Use this checklist to gauge whether your site would catch a source defect and manage the recall that follows. It mirrors the free worksheet available at the end of this article.

• Your DEL lists every activity you actually perform, including package or label, test, import and distribute, matched to each site.
• A written incoming inspection specification requires a defined visual and identity check for foreign or mismatched units on every received lot.
• Quality control quarantines, samples, tests and approves all incoming material before it enters packaging.
• Line clearance is a documented, signed and independently verified step before every packaging run.
• Only one product and one strength is packaged in a room at a time, unless a risk assessment proves no mix-up is possible.
• Reconciliation of bulk drug and printed packaging material is performed and every discrepancy is investigated before release.
• A quality agreement with each supplier defines recall notification timing, content and responsibilities.
• Lot traceability links each incoming source lot to every outgoing lot and customer.
• A written recall procedure is tested through a mock recall at least annually, with a reconciliation and effectiveness check.
• Returned goods are quarantined and never returned to saleable stock without documented quality control approval.

Common mistakes that turn a supplier defect into your recall

• Treating incoming inspection as a paperwork match. Checking the certificate of analysis without physically examining units lets a foreign tablet pass straight through.
• Skipping or back-dating line clearance. An unsigned or retrospective clearance is an inspection finding and leaves a real mix-up undetected.
• Releasing on an unexplained reconciliation gap. A count that does not balance is evidence of a mix-up, not a rounding issue.
• Assuming the fabricator owns the recall. If you packaged, relabelled or distributed the product, your retrieval duty is separate and parallel.
• Having no supplier quality agreement. Without agreed notification timing, you learn about a recall late, when options have narrowed.
• Weak traceability. If you cannot map a source lot to your outgoing lots in hours, your recall cannot be rapid, and a CAPA on this often fails for the reasons set out in our guide on why CAPA keeps failing.

Frequently asked questions

Is a repackager responsible when the source manufacturer recalls a drug in Canada?

Yes. Under section C.02.012 of the Food and Drug Regulations, any licence holder that packaged, labelled, imported or distributed the affected product must be able to recall it completely and rapidly. The duty to retrieve product you placed on the market is independent of the fabricator's recall, even if the defect originated upstream.

Do I need a Drug Establishment Licence just to repackage or relabel?

In most cases, yes. Packaging and labelling is a licensable activity under C.01A.008 of the Food and Drug Regulations, and the site must meet Good Manufacturing Practices in Division 2. Confirm the activities on your DEL match what your site actually does, and consult Health Canada's GUI-0002 for the current requirements.

What is line clearance and why do inspectors focus on it?

Line clearance is the documented check that a packaging area and equipment hold no product, component or label from a previous run before a new run begins. Inspectors focus on it because a missed clearance is one of the most common root causes of foreign-unit and mislabelling mix-ups, and the record is easy to verify.

How should incoming inspection catch a foreign tablet?

Your incoming specification should require a documented visual and identity examination of a defined sample from each received lot, looking for foreign or mismatched tablets, colour and debossing differences, chips and count errors. Quality control must approve the material before it enters packaging. A stray unit in the sample is a reject and an investigation, not a note.

What belongs in a supplier quality agreement for recall readiness?

At minimum: who notifies whom within what timeframe when a defect or recall arises, the information to be shared, each party's responsibilities for assessment and retrieval, and how changes are communicated. The goal is that you hear about a source recall from your supplier promptly, not from the news or a customer complaint.

How fast does a recall need to happen in Canada?

The regulation requires a system that permits complete and rapid recall. In practice, for a Class I or Class II situation you should be able to identify affected lots, quarantine stock and notify customers within hours. A mock recall at least once a year, with a reconciliation and effectiveness check, is how you prove the system works before you need it.

How MFLRC can help

MF License & Regulatory Consultants helps Canadian and international companies that fabricate, package, label, import or distribute drugs build controls that catch a defect before it becomes a recall. Our work in this area includes:

• GMP gap assessments and mock inspections against GUI-0001 and Division 2, focused on packaging, labelling and release.
• SOP development for incoming inspection, line clearance, reconciliation, returned goods and recall management.
• Supplier qualification and quality agreements that define recall notification and responsibilities.
• Drug Establishment Licence support to confirm your activities are correctly listed and your site is ready, including the changes in DEL Phase 2 modernization.
• Mock recall and CAPA programmes that test traceability and prove your system is rapid and complete.

Conclusion

Two recalls, eight days apart, for the same drug and the same defect, are a reminder that a mix-up does not respect the boundary between one company and the next. For a repackager or relabeller, the controls that catch a foreign tablet are not exotic. They are incoming inspection, line clearance, reconciliation and a recall system that is tested before it is needed. Each is written into Canadian GMP, and each is where an inspector will look. The firms that treat these controls as real work, rather than paperwork, are the ones that catch the problem at the line instead of on the evening news.

Sources and references

• Health Canada, Good Manufacturing Practices Guide for drug products (GUI-0001)
• Health Canada, Guidance on Drug Establishment Licences (GUI-0002)
• Food and Drug Regulations, C.R.C., c. 870 (Division 1A and Division 2)
• United States Food and Drug Administration, Recalls, Market Withdrawals and Safety Alerts / Enforcement Reports